BACKGROUND:Peritoneal mesothelioma (PeM) is an aggressive malignancy with a dismal prognosis and limited therapeutic options. Tumor-infiltrating natural killer (NK) cells play a pivotal role in anti-tumor immunity, yet their clinical significance in PeM remains unclear. This study aimed to investigate the correlation between NK cell infiltration levels and the main clinicopathologic characteristics and prognosis in PeM. METHODS:The study collected 109 postoperative specimens from PeM patients after cytoreductive surgery. Immunohistochemical staining was performed, and NK cell infiltration was quantified using QuPath-0.3.2 software. Uni- and multivariate analyses were performed to assess correlations between NK infiltration levels and clinicopathologic parameters. RESULTS:The 109 PeM patients in the study included 52 males (47.7%) and 57 females (52.3%) with a median age of 54 years (range, 25-72 years). Levels of NK infiltration were found to be low in 54 (49.5%) cases and high in 55 (50.5%) cases. Univariate analysis showed that a high NK infiltration level was negatively associated with the following five clinicopathologic factors: preoperative carbohydrate antigen (CA) 125 level, completeness of cytoreduction (CC), bleeding, red blood cell (RBC) transfusion, and ascites (all P < 0.05). Additionally. survival analysis demonstrated that a high NK infiltration level was associated with a better prognosis. CONCLUSION:Tumor-infiltrating NK cells may serve as prognostic biomarkers and guide personalized treatment strategies for PeM patients.

BACKGROUND:Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with high mortality rate and extremely poor prognosis. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays a critical role in disease progression and treatment response. This study aimed to analyze the correlation between the level of TILs and the main clinicopathological characteristics and prognosis of MPM. PATIENTS AND METHODS:A total of 143 postoperative specimens from patients with MPM following cytoreductive surgery were collected. Postoperative specimens were stained with hematoxylin and eosin (H&E). The level of TILs was quantitatively analyzed by QuPath 0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between TILs level and other conventional clinicopathological characteristics. RESULTS:Among the 143 patients with MPM, 73 were male (51.0%) and 70 were female (49.0%), with a median age of 55 (range 24-73) years. There were 72 (50.3%) cases with low TILs, and 71 (49.7%) cases with high TILs. Univariate analysis showed that TIL level (low versus high) was negatively correlated with the following seven clinicopathological factors: surgery history, Ki-67 index, preoperative CA125 level, peritoneal cancer index (PCI) index, bleeding volume, red blood cell (RBC) transfusion volume, and ascites volume (all P < 0.05). Multivariate analysis indicated that TIL level was independently negatively correlated with preoperative carbohydrate antigen (CA)125 level (odds ratio 0.394, 95% CI 0.179-0.866, P = 0.020). Cox regression analysis suggested that high TILs was independently associated with better prognosis of MPM. Moreover, a cohort of patients who received preoperative chemotherapy combined with targeted therapy were evaluated for response. Kaplan-Meier curve showed that high infiltration of TILs predicted better overall survival in patients undergoing treatment. CONCLUSIONS:TILs could be a useful indicator for predicting prognosis and guiding personalized treatment strategies in patients with MPM.

OBJECTIVE:Malignant peritoneal mesothelioma (MPM) is a rare primary malignant tumor with an extremely poor prognosis that currently lacks effective treatment options. This study investigated the in vitro and in vivo efficacy of natural killer (NK) cells for treatment of MPM. METHODS:An in vitro study was conducted to assess the cytotoxicity of NK cells from umbilical cord blood to MPM cells with the use of a high-content imaging analysis system, the Cell Counting Kit-8 assay, and Wright-Giemsa staining. The level of NK cell effector molecule expression was detected by flow cytometry and enzyme-linked immunosorbent assays. The ability of NK cells to kill MPM cells was determined based on live cell imaging, transmission electron microscopy, and scanning electron microscopy. An in vivo study was conducted to assess the efficacy and safety of NK cell therapy based on the experimental peritoneal cancer index, small animal magnetic resonance imaging, and conventional histopathologic, cytologic, and hematologic studies. RESULTS:NK cells effectively killed MPM cells through the release of effector molecules (granzyme B, perforin, interferon-γ, and tumor necrosis factor-α) in a dose- and density-dependent manner. The NK cell killing process potentially involved four dynamic steps: chemotaxis; hitting; adhesion; and penetration. NK cells significantly reduced the tumor burden, diminished ascites production, and extended survival with no significant hematologic toxicity or organ damage in NOG mice. CONCLUSIONS:NK cell immunotherapy inhibited proliferation of MPM cells in vitro and in vivo with a good safety profile.

Background. Inositol polyphosphate 4phosphatase type II (INPP4B) has been identified as a tumor repressor in several human cancers while its role in endometrial cancer has not been investigated yet. Therefore, the current study was designed to determine whether INPP4B participates in the progression of endometrial cancer by utilizing clinical data and experimental determination. Materials and methods. We first include six chemotherapy-treated patients with recurrent and metastatic endometrioid carcinoma to determine the relationship between INPP4B mutation and relative tumor burden. By using siRNA-mediated gene silencing and vector-mediated gene overexpression, we further determined the effect of manipulating INPP4B expression on the proliferation, invasion, and survival of endometrial cancer cells. Furthermore, the repressing effect of INPP4B together with its role in chemotherapy was further validated by xenograft tumor-bearing mice models. Western blot analysis was used to explore further downstream signaling modulated by INPP4B expression manipulation. Results. Two of the patients were found to have INPP4B mutations and the mutation frequency of INPP4B increased during the progression of chemotherapy resistance. Endometrial cancer cells with silenced INPP4B expression were found to have promoted tumor cell proliferation, invasion, and survival. Endometrial cancer cells overexpressing INPP4B were found to have decreased tumor cell proliferation, invasion, and survival. An in vivo study using six xenograft tumor-bearing mice in each group revealed that INPP4B overexpression could suppress tumor progression and enhance chemosensitivity. Furthermore, INPP4B overexpression was found to modulate the activation of Wnt3a signaling. Conclusion. The current study suggested that INPP4B could be a suppressor in endometrial cancer progression and might be a target for endometrial cancer treatment. Also, INPP4B might serve as a predictor of chemosensitivity determination.

OBJECTIVES:Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to distinguish biphasic mesothelioma (BM) from epithelioid mesothelioma (EM) with reactive stroma in peritoneum, as well as its prognostic value in PeM. METHODS:This is a retrospective study from June 2014 to December 2021. This study included 18 cases of BM and 27 cases of EM with reactive stroma, excluded sarcomatoid, and EM without reactive stroma cases, and clinicopathological information was collected. The associations between MTAP and BAP1 levels and clinicopathological features or prognosis were analyzed. Clinical follow-up data were reviewed to correlate with pathological prognostic factors using Kaplan-Meier estimator and univariate/multivariate Cox proportional hazards regression models. RESULTS:Loss/decrease of BAP1/MTAP was observed in 6 (33.3%) BM cases and 12 (44.4%) EM cases. In 5 (27.8%) cases, loss of or decreased BAP1/MTAP expression was observed in both EC and SC of BM. BAP1/MTAP loss/decrease was observed in 12 (44.4%) cases of only EC of EM but not in reactive stroma. Compared with histology alone, a combination of BAP1 and MTAP immunohistochemistry (IHC) in spindled PeM provides a more objective mean to distinguish BM from EM with reactive stroma. Loss/decrease of BAP1/MTAP was associated with peritoneal cancer index (PCI) score (P = 0.047) and completeness of cytoreduction (CC) score (P = 0.038). BM patients have worse overall survival (OS) than EM with reactive stroma (P = 0 .007). CONCLUSIONS:Combination of BAP1/MTAP by IHC is helpful for differential diagnosis of peritoneal BM from EM with reactive stroma. Nevertheless, BAP1/MTAP may help to evaluate the biological behavior of PeM.

BACKGROUND:Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. TOP2A expression is associated with cell proliferation and cell cycle progression. We aimed to demonstrate the expression profile of TOP2A in MPM and its correlation with clinicopathological features. METHODS:Clinicopathological information from 100 MPM cases was collected at Beijing Shijitan Hospital, Capital Medical University. Immunohistochemistry (IHC) was performed to evaluate TOP2A levels. The associations between TOP2A levels and clinicopathological features or prognosis were analyzed. Clinical follow-up data were reviewed to determine correlations among the pathological prognostic factors using the Kaplan-Meier estimator and univariate/multivariate Cox proportional hazards regression models. RESULTS:Among the 100 MPM patients, there were 48 males and 52 females, with a median age of 54 years (range: 24-72 years). The cutoff curve was used to find the boundary value of the TOP2A-positive rate. TOP2A positive rate ≥ 11.97 % accounted for 48 % in tumor tissue. The TOP2A-positive rate was not associated with sex, age, asbestos exposure, peritoneal carcinomatosis index (PCI) score, or completeness of cytoreduction (CC) score in MPM. Univariate analysis revealed survival-related pathological parameters, including asbestos exposure, CA125, histological type, PCI score, CC score, Ki-67 index, and TOP2A positive rate. Multivariate analysis identified that asbestos exposure history, PCI score, Ki-67 proliferation index and TOP2A positive rate in tissue are independent prognostic factors. CONCLUSIONS:High expression of TOP2A is linked to better prognosis of MPM.

Objective: To investigate the clinicopathological features of malignant peritoneal mesothelioma（MPM） in correlation with prognosis and independent prognostic factors. Methods: One hundred MPM specimens were collected at Beijing Shijitan Hospital, Capital Medical University, from January 2013 to December 2021. Asbestos exposure, CA125, ascites, peritoneal cancer index（PCI） score,complete cell reduction（CC） score, tumor–node–metastasis（TNM） staging, histological type, vascular tumor thrombus, nerve invasion and Ki-67 proliferation index were studied. Clinical follow-up data were reviewed to correlate with pathological prognostic factors using a Kaplan –Meier estimator and Cox proportional hazards regression model for both univariate and multivariate analyses.Results: The study participants comprised 48 males and 52 females. The median age was 54（24-72） years. There were 19 patients with asbestos exposure history（19%）, 90 patients with ascites（90%）, 58 patients with CA125 ≥35 U/mL（59%）, 56 patients with PCI scores of ≥25（56%）, 49 patients with CC scores of 0-1（49%）, and 51 patients with CC scores of 2-3（51%）. There were 79 cases of epithelioid type（79%）and 21 cases of non-epithelioid type（21%） MPM. There were 10 patients（10%） with stage Ⅰ disease, and 45 patients（45%） had stages Ⅱor Ⅲ disease, respectively. Univariate analysis revealed that the survival-related parameters included asbestos exposure, PCI score, CA125,histological type, Ki-67 proliferation index, and TNM stage. Multivariate analysis results revealed that the risk of death in patients with asbestos exposure history was 2.3 times higher than that in patients with no asbestos exposure history（95% confidence interval [CI]: 0.233-0.806, P=0.008）, the risk of death in patients with PCI scores of ≥25 was 2.9 times higher than that in patients with scores of ＜25（95% CI:0.200-0.612, P＜0.001）, and the risk of death in patients with Ki-67 ＞10% was 5.9 times higher than that in patients with Ki-67 ≤10%（95%CI: 0.072-0.401,P＜0.001）. There was significant difference in Ki-67 index between epithelioid and non-epithelioid MPM. Conclusions: Asbestos exposure history, PCI score, and Ki-67 proliferation index are independent prognostic factors in MPM patients.

PDF file - 90KB, Supplementary Figure 3 Confirmation of the surface expression of LSECtin on stable B16-mock and B16-LSECtin transfectants by flow cytometry.

Venous cystic adventitial disease (VCAD) is a rare vascular anomaly located in the common femoral vein in most cases. We describe the case of a 59-year-old female patient with right leg edema who was misdiagnosed with deep vein thrombosis of the lower extremity at another hospital. Magnetic resonance angiography revealed a round mass in the popliteal vein, with a narrow lumen. Considering the location of the lesion, absence of a history of deep venous thrombosis and trauma, and clinical manifestations, the diagnosis is likely a popliteal vein adventitial cyst. Segmental popliteal vein resection and reconstruction were performed using a cylindrical great saphenous vein graft. No joint connection was found during the operation, and the postoperative pathology confirmed VCAD.

恶性腹膜间皮瘤（malignant peritoneal mesothelioma，MPM）是原发于腹膜的罕见恶性肿瘤。33%~50%的弥漫MPM患者有石棉接触史。发病年龄以50~70岁多见。近85%的MPM有BAP1基因改变。本文报道1例31岁女性上皮样型MPM无石棉接触史伴有遗传性肿瘤基因STK11突变。临床表现为盆腔肿块。镜下排列呈管状、条状、筛状，肿瘤细胞为上皮样，中度核异型性、有核仁，间质富含小血管，伴有广泛的黏液变性。免疫组织化学广谱细胞角蛋白、波形蛋白、Calretinin、D2-40、间皮素细胞、WT-1均阳性。全外显子基因检测示遗传性肿瘤基因STK11突变。腹腔镜手术并化疗后3个月盆腔肿物复发。.

BackgroundStewart–Treves Syndrome in Primary Limb Lymphedema (STS-PLE) is an extremely rare malignant tumor. A retrospective analysis was conducted to elucidate the relationship between magnetic resonance imaging (MRI) findings and signs compared to pathology.MethodsSeven patients with STS-PLE were enrolled at Beijing Shijitan Hospital, Capital Medical University, from June 2008 to March 2022. All cases were examined by MRI. The surgical specimens were subjected to histopathological and immunohistochemical staining for CD31, CD34, D2-40, and Ki-67.ResultsThere were two different types of MRI findings. One was mass shape (STS-PLE I type) in three male patients, and the other was the “trash ice” d sign (STS-PLE II type) observed in four female patients. The average duration of lymphedema (DL) of STS-PLE I type (18 months) was shorter than that of STS-PLE II type (31 months). The prognosis for the STS-PLE I type was worse than that for the STS-PLE II type. Regarding overall survival (OS), the STS-PLE I type (17.3 months) was three times shorter than that of the STS-PLE II type (54.5 months). For STS-PLE I type, the older the STS-PLE onset, the shorter the OS. However, there was no significant correlation in STS-PLE II type. MRI was compared to histological results to provide an explanation for the differences in MR signal changes, especially on T2WI. Against a background of dense tumor cells, the richer the lumen of immature vessels and clefts, the higher the T2WI MRI signal (taking muscle signal as the internal reference standard) and the worse the prognosis, and vice versa. We also found that younger patients with a lower Ki-67 index (<16%) had better OS, especially for the STS-PLE I type. Those with stronger positive expression of CD31 or CD34 had shorter OS. However, the expression of D2-40 was positive in nearly all cases, and seemed not to be associated with prognosis.ConclusionsIn lymphedema, the richer the lumen of immature vessels and clefts based on dense tumor cells, the higher the T2WI signal on the MRI. In adolescent patients, the tumor often showed a “trash ice” sign (STS-PLE II-type) and prognosis was better than for the STS-PLE I type. While in middle-aged and older patients, tumors showed a mass shape (STS-PLE I type). The expression of immunohistochemical indicators (CD31, CD34, and KI-67) correlated with clinical prognosis, especially decreased Ki-67 expression. In this study, we determined it was possible to predict prognosis comparing MRI findings with pathological results.

Objectives To establish a Bayesian network (BN) model to predict the survival of patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods The clinicopathological data of 154 MPM patients treated with CRS + HIPEC at our hospital from April 2015 to November 2022 were retrospectively analyzed. They were randomly divided into two groups in a 7:3 ratio. Survival analysis was conducted on the training set and a BN model was established. The accuracy of the model was validated using a confusion matrix of the testing set. The receiver operating characteristic (ROC) curve and area under the curve were used to evaluate the overall performance of the BN model. Results Survival analysis of 107 patients (69.5%) in the training set found ten factors affecting patient prognosis: age, Karnofsky performance score, surgical history, ascites volume, peritoneal cancer index, organ resections, red blood cell transfusion, pathological types, lymphatic metastasis, and Ki-67 index (all p < 0.05). The BN model was successfully established after the above factors were included, and the BN model structure was adjusted according to previous research and clinical experience. The results of confusion matrix obtained by internal validation of 47 cases in the testing set showed that the accuracy of BN model was 72.7%, and the area under ROC was 0.74. Conclusions The BN model was established successfully with good overall performance and can be used as a clinical decision reference.

0 引言 弥漫性恶性腹膜间皮瘤(diffuse malignant peri-toneal mesothelioma, DMPM)是一种原发于腹膜间皮细胞的罕见高度恶性肿瘤,其发病率为(1～2)/106,占所有间皮瘤的7％～20％[1-3].其临床表现多样,症状无特异性.最常见的症状为腹痛和腹胀,其他症状包括体重减轻、腹壁疝、腹部肿块或厌食等,侵袭性较强的间皮瘤亚型亦可表现为快速进展性腹胀和肠梗阻[4].此外,极少数患者在疾病进展过程中会出现多种副肿瘤综合征(paraneoplastic syndrome, PS),此类患者往往临床一般情况较差,诊疗困难.

Background Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecular chaperone that binds histones and may play a key role in the development and progression of tumors. This study aimed to analyze the correlation between the expression level of NPM2 and the main clinicopathological characteristics and prognosis of MPM. Methods Ninety-two postoperative specimens from MPM patients following cytoreductive surgery were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics. Results Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24–73). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, and serious adverse events (SAEs) (all P < 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95% CI : 0.317–0.959, P = 0.042] and vascular tumor emboli ( OR = 0.092, 95% CI = 0.011–0.770, P = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM. Conclusions Loss of NPM2 expression is a potential immunohistochemical marker for MPM.

Abstract Background To explore the correlation between the expression level of nucleoplasmin 2 (NPM2) and the main clinicopathological characteristics and prognosis of malignant peritoneal mesothelioma (MPM). Methods Ninety-two postoperative specimens from MPM patients following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics. Results Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24–73). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, serious adverse events (SAEs) (all P < 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95%CI: 0.317–0.959, P = 0.042], vascular tumor emboli (OR = 0.092, 95%CI = 0.011–0.770, P = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM. Conclusions Loss of NPM2 expression is a potential immunohistochemical marker for MPM.

Objective:To evaluate the clinical effect of surgical resection and local advancement flap repair of the postoperative chronic refractory incision.Methods:From February 2016 to January 2021, 42 patients with postoperative chronic refractory incision were selected from the Department of Plastic and Aesthetic Surgery, Beijing Shijitan Hospital, Capital Medical University. After improved the preoperative examination, the patients were scheduled to undergo surgical repair. The incision line was designed at 0.5 to 1.0 cm around the refractory incision. The incision and the lesion of the base were completely removed, down to the deep fascia or sarcolemma under local or general anesthesia, and the defect was repaired by local advancement flap. The blood supply of the flap and the incision healing time and condition of wound healing were observed. Pathological examination was performed to observe the inflammatory reaction and inflammatory cell infiltration of the incision and peripheral tissue of the incision.Results:The blood supply of the local flap was normal after operation, and there were no signs of infection such as redness, swelling and pain. All patients healed in Ⅰ stage. The incision healing time was (12.0±3.0) days. Pathological examination showed that the inflammation in the center of the incision was serious, lymphocyte infiltration (140 ± 21) cells /HPF, and the structure of the cutting edge was normal. Following up for 2- 6 months, there was no recurrence of the wound.Conclusions:The refractory incision and the inflammatory lesion at 0.5-1.0 cm around the incision are completely removed, and the wound surface can be repaired in Ⅰ stage with local advancement flap. There is no recurrence after follow-up, and the operation effect is satisfactory. It is worthy of clinical application and promotion.

Objectives To investigate independent factors for the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of diffuse malignant peritoneal mesothelioma (DMPM). Methods The clinical database of 110 DMPM patients treated with CRS + HIPEC at our hospital was retrospectively analyzed. Independent prognostic factors were screened using univariate and multivariate analyses and the safety of the perioperative period was evaluated based on adverse events. Results Among the 110 patients with DMPM, 34 (30.9%) had a peritoneal cancer index (PCI) < 20 and 76 (69.1%) had PCI >= 20; 59 (53.6%) patients achieved completeness of cytoreduction (CC) 0/1 and 51 (46.4%) cases achieved CC 2/3. At the median follow-up of 43.3 (95%CI: 37.3-49.4) months, 48 (43.6%) patients were still alive and 62 (56.4%) patients died. The median overall survival was 32.6 months. Serious adverse events (SAEs) occurred in 41 patients (37.3%) and the perioperative mortality rate was 2.7%. Univariate analysis identified nine prognostic factors: Karnofsky performance status score, perioperative tumor markers, PCI, red blood cell infusion, pathological type, vascular tumor emboli, lymphatic metastasis, Ki-67 index, and perioperative SAEs (all p < 0.05). Multivariate analysis identified four independent prognostic factors: pathological type (p = 0.007), vascular tumor emboli (p = 0.044), Ki-67 index (p = 0.044), and SAEs (p = 0.004). Conclusions CRS + HIPEC for DMPM treatment resulted in prolonged survival with acceptable safety. Tumor pathology and SAEs are key factors for successful CRS + HIPEC.

目的:探讨甲状腺乳头状癌(PTC)患者颈部淋巴结转移与原发灶临床病理特征和BRAFV600E基因突变的关联性,阐明PTC患者颈部淋巴结转移的影响因素.方法:选择因PTC在本院手术治疗的患者,回顾性分析其临床资料,包括患者年龄,性别,原发灶部位和数量,淋巴结转移数量和位置;病理学资料,包括肿瘤的位置、大小、数目和包膜侵犯,瘤周纤维包裹,检出砂粒体,脉管和神经受累.检测PTC组织中BRAF V600E基因突变情况,分析颈部淋巴结转移与PTC患者临床特征、病理学特点和BRAF V600E基因突变的关联性,采用多因素Logistic回归模型分析PTC患者颈部淋巴结转移的影响因素.结果:共选择PTC患者321例,其中发生颈部淋巴结转移者129例(40.2％).279例(86.9％)患者伴有BRAF V600E基因突变,但BRAF V600E基因突变与PTC淋巴结转移无关联(P>0.05).PTC患者颈部淋巴结转移与患者发病年龄、肿瘤最大径、甲状腺双侧叶多原发灶、检出砂粒体和脉管受侵有关联(P<0.05或P<0.01).多因素Logistic回归分析,PTC患者年龄(OR=0.729,95％CI:0.600～0.885)、肿瘤最大径(OR=1.796,95％CI:1.326～2.433)、原发灶数量(OR=1.947,95％CI:1.225～3.096)、检出砂粒体(OR=2.578,95％CI:1.037～6.409)和脉管受侵(OR=8.856,95％CI:1.929～40.656)是PTC患者淋巴结转移的影响因素.结论:PTC患者发生颈部淋巴结转移与患者年龄、肿瘤最大径、原发灶数量、检出砂粒体和脉管受侵有关联,与BRAF V600E基因突变无关联.